Company profile: XNK Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage autologous NK cell–based immunotherapies for cancer, leveraging a proprietary platform for development and manufacture. Pipeline includes evencaleucel in Phase II for multiple myeloma with isatuximab, and preclinical candidates XNK02 (AML), XNK03 (urothelial cancer), and XNK04 (hepatocellular carcinoma). Holds a GMP manufacturing license.
Products and services
- GMP Manufacturing License: GMP-compliant facility fabricates clinical products, enabling in-house production capacity for autologous NK cell-based products using the company’s proprietary technology platform
- Evencaleucel: Autologous NK cell therapy being evaluated in phase II for multiple myeloma in combination with isatuximab
- XNK02: Autologous NK cell-based product for acute myeloid leukemia (AML), currently in preclinical development, targeting cancer through NK cell therapy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to XNK Therapeutics
Medicago
HQ: Canada
Website
- Description: Provider of vaccines in Canada, leveraging proprietary plant-based Proficia and Virus-Like Particles (VLP) technologies; focuses on the research, development, production, and commercialization of vaccines, with product candidates including an H5N1 pandemic candidate.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medicago company profile →
Alder BioPharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical solutions leveraging proprietary technologies to accelerate antibody discovery and development. The company identifies, develops, produces, and markets its own antibody therapeutics aimed at generating better and safer treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alder BioPharmaceuticals company profile →
Tubulis
HQ: Germany
Website
- Description: Provider of chemotherapeutic medications for cancer and chronic disorders, developing disease-matched protein-drug conjugates (ADCs) using proprietary P5 conjugation chemistry and the Tubutecan linker-payload platform. Products include TUB-030 targeting 5T4 in solid tumors for long-lasting anti-tumor activity and TUB-040 targeting NaPi2b in ovarian and lung cancer for stable, potent delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tubulis company profile →
Pheast
HQ: United States
Website
- Description: Provider of checkpoint therapies to harness the innate immune system, including PHST001, an anti-CD24 antibody that blocks a key macrophage ‘don’t eat me’ signal on cancer cells to induce an anti-cancer immune response, and a proprietary discovery platform that uncovers tumor-specific ‘don’t eat me’ signals to create novel macrophage-targeted immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pheast company profile →
Memo Therapeutics
HQ: Switzerland
Website
- Description: Provider of antibody discovery and immune repertoire analysis, featuring the MemoMAB platform to create and bank recombinant copies of individual B cell/antibody repertoires for high-throughput functional screening to identify potent, ultra-rare antibodies. Offers human antibody repertoire libraries, discovery in humans and rabbits, and AntiBKV for BK virus in kidney transplant recipients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Memo Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for XNK Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to XNK Therapeutics
2.2 - Growth funds investing in similar companies to XNK Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for XNK Therapeutics
4.2 - Public trading comparable groups for XNK Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →